Cyltezo Pen 40 MG/0.8 ML - Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (6 count)

RxCUI: 2640903
RxNorm name: Cyltezo Pen 40 MG/0.8 ML - Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (6 count)
Display name: Cyltezo Pen 40 MG/0.8 ML - Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (6 count)
Full name: Cyltezo Pen 40 MG/0.8 ML - Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (6 count)
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:38:47

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761058	Cyltezo	adalimumab-adbm	351(k) Interchangeable	Rx	2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Cyltezo	ADALIMUMAB-ADBM	Boehringer Ingelheim Pharmaceuticals, Inc.	115ea79b-7209-7f19-b35d-36ec0828fbf5	2026-05-22	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2640903

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
115ea79b-7209-7f19-b35d-36ec0828fbf5	Cyltezo Pen 40 MG/0.8 ML - Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (6 count)	SY	17	These highlights do not include all the information needed to use CYLTEZO safely and effectively. See full prescribing information for CYLTEZO. CYLTEZO ® (adalimumab-adbm) injection, for subcutaneous use Initial U.S. Approval: 2017 CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betw	20260303
115ea79b-7209-7f19-b35d-36ec0828fbf5	CYLTEZO Pen 40 MG/0.8 ML - Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (6 count)	PSN	17	These highlights do not include all the information needed to use CYLTEZO safely and effectively. See full prescribing information for CYLTEZO. CYLTEZO ® (adalimumab-adbm) injection, for subcutaneous use Initial U.S. Approval: 2017 CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betw	20260303
115ea79b-7209-7f19-b35d-36ec0828fbf5	{6 (0.8 ML adalimumab-adbm 50 MG/ML Auto-Injector [Cyltezo]) } Pack [Cyltezo Pen 40 MG/0.8 ML Starter Package for Crohn's Disease or Ulcerative Colitis]	BPCK	17	These highlights do not include all the information needed to use CYLTEZO safely and effectively. See full prescribing information for CYLTEZO. CYLTEZO ® (adalimumab-adbm) injection, for subcutaneous use Initial U.S. Approval: 2017 CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betw	20260303